The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | One versus two inductions to attain CR1 in patients with AML undergoing alloSCT with PTCy
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, shares the findings of a registry-based retrospective analysis that evaluated the impact of one versus two inductions to attain first complete remission (CR1) in patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (alloSCT) with post-transplant cyclophosphamide (PTCy). Prof. Nagler notes that while achieving remission after one induction is typically associated with better transplant outcomes, this difference is not observed in patients receiving PTCy, suggesting a new biology at play. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
